First-Quarter 2025 Sales and Earnings Merck & Co., Inc., Rahway, N.J., USA April 24, 2025 -- 1 of 29 -- Agenda 2 Agenda Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Question & Answer Session -- 2 of 29 -- 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA -- 3 of 29 -- Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer 4 -- 4 of 29 -- 5 Q1 2025 total company performance and pipeline progress $15.5B Q1 Worldwide Sales Strength in Oncology and Animal Health Meaningful contributions from new launches Cardiometabolic Important results for WINREVAIR from Phase 3 ZENITH trial Licensed HRS-5346, oral Lp(a) inhibitor, from Hengrui Pharma Infectious Disease Results from two Phase 3 switch studies for islatravir + doravirine for HIV treatment in adults Oncology Presentation of data and FDA acceptance of BLA for subcutaneous pembrolizumab with berahyaluronidase-alfa FDA acceptance of sBLA for KEYTRUDA in earlier-stage HNSCC -- 5 of 29 -- 6 Delivering the next wave of innovation Well positioned to successfully navigate through the KEYTRUDA LOE period Executing Business Development Actively pursuing additional science-driven value-creating transactions Advancing Early- and Late-Phase Pipeline Nearly tripled late-phase pipeline since 2021 Launching New Growth Drivers >$50B commercial opportunity by mid-2030s from recent launches and late-phase pipeline -- 6 of 29 -- “Confident in our strategic direction, our commitment to research and development as the source for sustainable value-creation, and our enduring promise to positively impact patients” 7 -- 7 of 29 -- Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer 8 -- 8 of 29 -- 9 Q1 worldwide performance driven by demand for our innovative portfolio 1. Worldwide Sales includes Other Revenue 2. Excludes sales of GARDASIL in China of $1.3 billion in 1Q24 and $193 million in 1Q25 Human Health $13.6B-3% decrease -1% ex-exchange +5% ex-GARDASIL China2 +7% ex-GARDASIL China, ex-exchange $15.5B-2% decrease +1% ex-exchange +6% ex-GARDASIL China 2 +8% ex-GARDASIL China, ex-exchange WORLDWIDE SALES1 Animal Health $1.6B+5% growth +10% ex-exchange -- 9 of 29 -- 10 Oncology: KEYTRUDA continues to benefit patients and drive growth KEYTRUDA sales of $7.2B increased 6%, driven by increased uptake from earlier-stage cancers and robust demand from metastatic indications ‒ In earlier-stage settings, growth driven by increased utilization in resectable TNBC, RCC and NSCLC ‒ In metastatic disease, growth driven by increased use of KEYTRUDA in combination with Padcev in first-line, locally advanced urothelial cancer, as well as KEYTRUDA in combination with chemotherapy in 1L endometrial cancer ‒ In the U.S., growth negatively impacted by ~$250M due to timing of wholesaler purchases 1Q23 1Q24 1Q25 $5.8B +24% $7.2B +6%$6.9B +24%1 Growth rates exclude the impact of foreign exchange. 1. Includes ~4 percentage points of negative impact of foreign exchange substantially all of which was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases. -- 10 of 29 -- 11 Oncology: Important contributions across broad portfolio WELIREG sales grew 63%, driven by increased uptake in certain adult patients with previously treated advanced RCC in the U.S ‒ Now market leader for treatment of adult patients with advanced RCC following indicated prior therapies Lynparza 1 sales grew 8%, primarily due to higher demand in the U.S. and certain international markets Lenvima 2 sales grew 2%, primarily due to higher demand in the U.S. Growth rates exclude the impact of foreign exchange. 1. In collaboration with AstraZeneca 2. In collaboration with Eisai 1Q23 1Q24 1Q25 $292M +7% $275M +8% $312M +8% 1Q23 1Q24 1Q25 $255M +10% $232M +5% $258M +2% 1Q23 1Q24 1Q25 $85M +102% $42M +128% $137M +63% -- 11 of 29 -- 12 Vaccines: Broad vaccines portfolio driving global impact GARDASIL sales of $1.3B decreased 40%, driven by continued soft demand in China where channel inventories remain elevated ‒ In the U.S., sales benefitted from price and demand ‒ Outside the U.S. and China, growth driven by higher overall demand including catch-up cohort in Japan CAPVAXIVE sales of $107M, driven primarily by demand from retail pharmacy segment VAXNEUVANCE sales of $230M increased 7%, driven by ongoing launches in international markets, partially offset by competitive pressures in the U.S. 1Q23 1Q24 1Q25 $1.7B +40% 1Q23 1Q24 1Q25 $2.2B +17% $1.3B -40% $2.0B +43% $106M $219M +106% $230M +7% Growth rates exclude the impact of foreign exchange. -- 12 of 29 -- 13 Cardiovascular: Successful ongoing launch of WINREVAIR K 5K 10K 15K 20K 25K 30K 35K 40K U.S. Launch Progress Total Prescriptions (TRx) U.S.: Continued growth in new patient starts and TRx ‒ >1,400 new patients prescribed in the quarter ‒ ~6,600 total patients prescribed since launch ‒ ~5,200 patients with claims approved by payers started treatment since launch ‒ >38,000 total prescriptions filled since launch Strong breadth and depth of prescribers ‒ ~1,100 physicians have written at least one prescription since launch ‒ Steady increase in percentage of prescriptions for patients whose background PAH therapies do not include a prostacyclin Achieved coverage for >70% of lives since launch Ex-U.S.: Progressing with launches ‒ Anticipate securing reimbursement in other European countries in 2H25 Global Q1 sales of $280M -- 13 of 29 -- 14 Animal Health: Robust growth driven by demand for livestock products Animal Health sales increased 10% to $1.6B ‒ Livestock sales grew 16%, driven by higher demand across all species, as well as benefit from timing of ruminant sales and inclusion of sales from recently expanded aqua portfolio ‒ Companion Animal sales growth of 3% reflects price Growth rates exclude the impact of foreign exchange. 1. Includes ~3 percentage points of negative impact of foreign exchange, of which ~2 percentage points was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases. 1Q23 1Q24 1Q25 $1.5B +5% $1.5B +4%1 $1.6B +10% -- 14 of 29 -- 15 Q1 2025 non-GAAP financial results summary 1 $ in billions, except EPS amounts 1. The company is providing certain 2025 and 2024 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q1 2024 includes a charge of $0.26 per share for the acquisition of Harpoon. 3. Q1 2025 GAAP EPS of $2.01 Q1 2025 Q1 2024 Change Change Ex-FX Sales $15.5 $15.8 -2% +1% Non-GAAP Gross Margin 82.2% 81.2% +1.0pts +1.5pts Non-GAAP Operating Expenses $6.1 $6.4 -4% -3% Non-GAAP Tax Rate 14.2% 16.1% -1.9pts N/A Non-GAAP EPS2,3 $2.22 $2.07 +7% +12% -- 15 of 29 -- 16 Updated 2025 financial outlook 1. Guidance does not assume any additional significant potential business development transactions. Prior Guidance Updated Guidance Key Assumptions Revenue $64.1B to $65.6B $64.1B to $65.6B • Now assumes ~1 percentage point FX headwind • Implies +0% to +2% nominal (+1% to +3% ex-FX) Non-GAAP Gross Margin Rate ~82.5% ~82.0% • Now includes ~$200M of costs related to tariffs implemented to date Non-GAAP Operating Expenses1 $25.4B to $26.4B $25.6B to $26.6B • Now includes $200M anticipated upfront payment related to license agreement with Hengrui Pharma Other (Income) / Expense ~$300M to ~$400M of expense ~$300M to ~$400M of expense Tax Rate ~16.0% to 17.0% ~15.5% to 16.5% Shares Outstanding ~2.53B ~2.51B Non-GAAP EPS1 $8.88 to $9.03 $8.82 to $8.97 • Now includes ~$0.06 charge related to license agreement with Hengrui Pharma • Now assumes negative impact from FX of >$0.20 -- 16 of 29 -- 17 Key modeling considerations GARDASIL Family1 • Following successful HPV catch-up vaccination program in Japan, expect uptake to moderate as future sales will predominantly reflect the primary age cohort • Therefore, global GARDASIL growth ex-China, while still strong, is anticipated to slow going forward KEYTRUDA • Timing of wholesaler purchases negatively impacted U.S. sales by ~$250M in 1Q25, and will positively impact sales by roughly the same amount in 3Q25 JANUVIA Family2 • Lowered U.S. list prices at the beginning of 2025 which will reduce rebate amount paid to Medicaid • As a result, expect higher net sales in the U.S. in 2025 • 1Q25 U.S. sales also benefitted by >$100M from favorable one-time true ups 1. GARDASIL Family includes GARDASIL and GARDASIL 9 2. JANUVIA Family includes JANUVIA, JANUMET and JANUMET XR -- 17 of 29 -- 18 Remain committed to balanced capital allocation strategy Q1 Spend ($ in billions) 1 Continue to invest in our pipeline and business while augmenting our pipeline with value-enhancing business development $3.1 $1.3 $2.0 $1.5 $1.2 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Capital allocation order of priority 1. Reflects quarter spend 2. Reflects R&D excluding Business Development 2 -- 18 of 29 -- Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories 19 -- 19 of 29 -- 20 Broadening our impact in cardiometabolic research WINREVAIR - ZENITH Study HRS-5346 • First study in PAH to use a primary endpoint comprised entirely of major morbidity and mortality events • First Phase 3 study in PAH stopped early for ‘overwhelming efficacy’ • Profound risk reduction of 76% on composite endpoint of all-cause death, PAH-worsening related hospitalization (≥24 hours), and lung transplantation in patients with advanced PAH at high risk of mortality despite maximally tolerated background therapy vs placebo ‒ Early and sustained separation between treatment groups • Loss of clinical equipoise in HYPERION: stopped early and moving to final analysis based on totality of data in WINREVAIR clinical program to date • Entered exclusive license agreement with Hengrui Pharma to develop investigational oral small molecule Lp(a) formation inhibitor • Hengrui recently initiated Phase 2 clinical trial in China for HRS-5346 • Planning robust global clinical development program -- 20 of 29 -- 21 Progress across vaccines and infectious disease programs Vaccines HIV CAPVAXIVE • EC granted approval for active immunization for prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in adults GARDASIL • NMPA of China approved GARDASIL 9 to help prevent certain HPV-related cancers and diseases in males 16 to 26 years old • Presented detailed results from two pivotal Phase 3 trials evaluating investigational, once-daily, oral fixed dose combination of doravirine and islatravir, an investigational NRTTI, in treatment-experienced adults with HIV-1 infection at CROI1 ‒ Both trials met primary efficacy success criteria for non- inferiority to comparator antiretroviral therapies and primary safety objectives ‒ Plan to submit applications for marketing authorization by mid-year 1. Conference on Retroviruses and Opportunistic Infections -- 21 of 29 -- Subcutaneous pembrolizumab 22 Continuing to advance our broad oncology program 1. European Lung Cancer Congress KEYTRUDA in Earlier Stage WELIREG Announced detailed findings from 3475A- D77 pivotal Phase 3 trial, evaluating six- week dosing regimen of the investigational subcutaneous fixed dose combination of pembrolizumab and berahyaluronidase alfa, with chemotherapy, versus intravenous KEYTRUDA with chemotherapy at ELCC1 ‒ Study met dual primary endpoints, demonstrating non-inferior pharmacokinetics with a median injection time of ~2 minutes ‒ FDA set PDUFA date of September 23 rd ‒ Seeking approval for six-week and three- week dosing options ‒ EMA reviewing application for approval KEYNOTE-689: FDA granted priority review for KEYTRUDA as part of a perioperative treatment regimen for patients newly diagnosed with resectable, locally advanced HNSCC ‒ FDA set PDUFA date of June 23 rd If approved, would mark 10th indication of a KEYTRUDA based regimen for treatment of certain earlier stage cancers: ‒ Lung: KEYNOTE-671, KEYNOTE-091 ‒ Renal: KEYNOTE-564 ‒ Skin: KEYNOTE-054, KEYNOTE-716, KEYNOTE-629 ‒ Breast: KEYNOTE-522 ‒ Cervical: KEYNOTE-A18 ‒ Bladder: KEYNOTE-057 EC conditionally approved WELIREG for treatment of adults with: ‒ vHL disease who require therapy for associated, localized RCC, CNS, hemangioblastomas, or pancreatic NET tumors, and for whom localized procedures are unsuitable based on LITESPARK-004 ‒ Advanced clear cell RCC that progressed following two or more lines of therapy that included a PD-1 or PD-L1 inhibitor and at least two VEGF targeted therapies based on LITESPARK-005 -- 22 of 29 -- 23 Key upcoming dates and milestones JUNE 2 Save the Date: ASCO Investor Event in Chicago Upcoming Milestones: Oncology • KEYNOTE-689 in locally advanced HNSCC - PDUFA date June 23rd • Subcutaneous pembrolizumab - PDUFA date September 23rd RSV • Clesrovimab in RSV to help protect infants during their first RSV season - PDUFA date June 10 th Cardiometabolic • Enlicitide for treatment of hypercholesterolemia – results from three Phase 3 registration-enabling studies • WINREVAIR ‒ Phase 2 CADENCE study – PCD scheduled for Fall ‒ Phase 3 HYPERION study – final data readout HIV • Islatravir/doravirine regimen – regulatory filing in U.S • MK-8527 Phase 2a study for PrEP – data readout -- 23 of 29 -- Q&A Robert M. Davis Chairman and Chief Executive Officer Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Caroline Litchfield Executive Vice President and Chief Financial Officer Peter Dannenbaum Senior Vice President, Investor Relations -- 24 of 29 -- 25 Appendix -- 25 of 29 -- 26 Q1 2025 GAAP financial results summary $ in billions, EPS amounts 1. 1Q24 GAAP results includes $656 million charge, or $0.26 negative EPS impact, for the acquisition of Harpoon Q1 2025 Q1 2024 Change Change Ex-FX Sales $15.5 $15.8 -2% +1% Operating Expenses1 $6.2 $6.5 -5% -3% Tax Rate 13.9% 15.9% -2.0pts N/A GAAP EPS1 $2.01 $1.87 +7% +13% -- 26 of 29 -- 27 Capital allocation: Trailing twelve months $12.4 $3.9 $7.9 $5.1 $2.3 $0 $3 $6 $9 $12 $15 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase ~$20B Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$11B in the U.S. Billions Well-positioned balance sheet with capacity to fund additional value-enhancing business development opportunities Order of priority 2 1 E $1.84 $1.88 $1.92 $2.20 $2.44 $2.60 $2.76 $2.92 $3.08 $3.24 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025E Dollars per share +2% +2% +2% +11% +15% +7% +6% +6% +5% +5% 1. Reflects R&D excluding Business Development 2. Includes BD payments reflected in operating cash flow Over the past 12 months Capital investments 2024 to 2028 Commitment to the dividend -- 27 of 29 -- 28 Driving value for patients and shareholders by progressing our pipeline Key regulatory milestones since the last earnings call: In the U.S., the FDA: • Accepted for review a BLA for subcutaneous pembrolizumab with berahyaluronidase alfa across all previously approved solid tumor indications for KEYTRUDA based on 3475A-D77 • Accepted for priority review the sBLA for KEYTRUDA plus standard of care as perioperative treatment for resectable locally advanced head and neck squamous cell carcinoma based on KEYNOTE-689 In the EU, the European Commission: • Approved CAPVAXIVE for active immunization for the prevention of invasive disease and pneumonia caused by certain types of streptococcus pneumoniae in adults • Approved KEYTRUDA plus chemotherapy as first-line treatment for adult patients with unresectable non-epithelioid metastatic malignant pleural mesothelioma based on IND.227/KEYNOTE-483 • Conditionally approved WELIREG for the treatment of adult patients with VHL disease who require therapy for associated, localized RCC, CNS, hemangioblastomas, or pNET, and for whom localized procedures are unsuitable based on LITESPARK-004 • Conditionally approved WELIREG for the treatment of adult patients with advanced clear cell RCC that progressed following two or more lines of therapy that included a PD-1 or PD-L1 inhibitor and at least two VEGF-targeted therapies based on LITESPARK-005 In China, the NMPA: • Approved GARDASIL-9 for the prevention of certain HPV-related cancers and diseases in males 16-26 years of age Key data & clinical advancements since the last earnings call: Presented data for: • Phase 3 ZENITH trial at the American College of Cardiology’s Annual Scientific Session and Expo demonstrating WINREVAIR significantly reduced the risk of major morbidity and mortality events in adults with PAH WHO FC III or IV at high risk of mortality • Pivotal 3475A-D77 Phase 3 trial at the European Lung Cancer Congress 2025 showing that pembrolizumab with berahyaluronidase alfa administered subcutaneously (subcutaneous pembrolizumab) was non-inferior to pembrolizumab IV with respect to PK endpoints, and results across reported safety and efficacy endpoints were consistent between the treatment arms • Two pivotal Phase 3 trials at the 32nd Conference on Retroviruses and Opportunistic Infections evaluating the once-daily, oral, two-drug regimen of doravirine/islatravir demonstrating non-inferiority and a similar safety profile to comparator antiretroviral therapies in adults with virologically suppressed HIV-1 Initiated Phase 3 study evaluating: • Zilovertamab vedotin, an investigational ROR1 antibody-drug conjugate, for the treatment of patients with previously untreated diffuse large B-cell lymphoma (waveLINE-010) -- 28 of 29 -- MK-8591A (doravirine+islatravir) 4 HIV-1 Infection MK-8591D (islatravir+lenacapavir) 1,4 HIV-1 Infection LAGEVRIO (MK-4482) 1,5 COVID-19 Antiviral (U.S.) 29 Broad and innovative pipeline to address significant unmet medical needs As of April 24, 2025 Phase 3 Oncology MK-1022 (patritumab deruxtecan) 1 NSCLC (EU) MK-1026 (nemtabrutinib) Hematological Malignancies MK-1084 2 NSCLC MK-1308A (quavonlimab +pembrolizumab) RCC MK-2140 (zilovertamab vedotin) Hematological Malignancies MK-2400 (ifinatamab deruxtecan) 1 Esophageal SCLC MK-2870 (sacituzumab tirumotecan) 1,3 Breast Cervical Endometrial Gastric NSCLC Ovarian MK-3543 (bomedemstat) Myeloproliferative Disorders KEYTRUDA (MK-3475) Hepatocellular (EU) Ovarian SCLC MK-5684 (opevesostat) Prostate LYNPARZA (MK-7339) 1,2 NSCLC SCLC LENVIMA (MK-7902) 1,2 Esophageal V940 (intismeran autogene) 1,2 Melanoma NSCLC Infectious Disease MK-7240 (tulisokibart) Crohn’s Disease Ulcerative Colitis Immunology Cardiometabolic MK-0616 (enlicitide decanoate) Hypercholesterolemia MK-30006 Diabetic Macular Edema Ophthalmology Phase 2 MK-2870 (sacituzumab tirumotecan) 1,3 Biliary Bladder CRC Neoplasm Malignant Pancreatic KEYTRUDA (MK-3475) Advanced Solid Tumors Prostate MK-3475A (pembrolizumab + berahyaluronidase alfa) cSCC Hematological Malignancies MK-5909 (raludotatug deruxtecan) 1 Biliary Bladder Cervical CRC Endometrial Gastric Ovarian Pancreas RCC SCLC V940 (intismeran autogene) 1,2 Bladder RCC MK-1022 (patritumab deruxtecan) 1,3 Biliary Bladder Breast Cervical CRC Endometrial Esophageal Gastric HCC HNSCC Melanoma Ovarian Pancreas Prostate MK-1308 (quavonlimab +pembrolizumab) 2 NSCLC MK-2400 (ifinatamab deruxtecan) 1 Biliary Bladder Breast Cervical CRC Endometrial HCC HNSCC Melanoma Ovarian Pancreas Oncology V181 Dengue Fever Virus Vaccines Infectious Disease MK-8527 HIV-1 PrEP MK-8591B (islatravir+MK-8507) HIV-1 Infection MK-5475 PH-COPD MK-6024 (efinopegdutide) MASH WINREVAIR (MK-7962) Pulmonary Hypertension due to Left Heart Disease Cardiometabolic MK-6194 Lupus Vitiligo MK-7240 (tulisokibart) Systemic Sclerosis Immunology MK-1167 Alzheimer’s Neuroscience Under regulatory review Oncology KEYTRUDA (MK-3475) HNSCC (US, JPN) Mesothelioma (JPN) MK-3475A (pembrolizumab + berahyaluronidase alfa) Previously Approved Solid Tumors (U.S.) Previously Approved Tumors (EU) MK-1022 (patritumab deruxtecan) 1,7 NSCLC (US) WELIREG (MK-6482) Advanced RCC (JPN) Certain VHL Tumors (JPN) PPGL (US) Vaccines CAPVAXIVE (V116) Pneumococcal Vaccine Adult (JPN) Infectious Disease MK-1654 (clesrovimab) Respiratory Syncytial Virus (US, EU) Cardiometabolic WINREVAIR (MK-7962) Pulmonary Arterial Hypertension (JPN) 1. Being developed in a collaboration 2. Being developed in combination with KEYTRUDA 3. Being developed as monotherapy and/or in combination with KEYTRUDA 4. On partial clinical hold for higher doses of islatravir than those used in current clinical trials 5. Available in the U.S. under Emergency Use Authorization 6. Program is in Phase 2/3 study 7. In June 2024, FDA issued a CRL for the BLA for patritumab deruxtecan. Merck is working with Daiichi Sankyo to address FDA feedback -- 29 of 29 --